Peter Blume-Jensen - 25 Aug 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Reporting relationship: President and CEO, Director
Issuer ticker: ACRV
Reported as of: 25 Aug 2026
Net transaction value: -$30,969
SEC form: 4
Accepted by SEC: 27 Aug 2026, 16:14:53 UTC
Prior SEC filing: 20 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen

Key filing fact

Peter Blume-Jensen filed Form 4 for Acrivon Therapeutics, Inc. (ACRV) on 27 Aug 2026.

Key facts

This page summarizes Peter Blume-Jensen's Form 4 filing for Acrivon Therapeutics, Inc. (ACRV).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 27 Aug 2026, 16:14.

Change

Previous filing in this sequence was filed on 20 Aug 2026.
Current net transaction value: -$30,969.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001950499 Primary reporting owner

Blume-Jensen Peter

Relationship: President and CEO, Director
Address: C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN
Signature: /s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen
Signature date: 27 Aug 2026

CIK 0001950501

Masson Kristina

Relationship: EVP - Business Operations, Director
Address: C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN
Signature: /s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson
Signature date: 27 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACRV transaction

Common Stock

Sale

Transaction value: $30,969
Shares: -14,036
Change %: -0.63%
Price: $2.21
Shares after: 2,230,052
Date: 25 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F3

ACRV transaction

Common Stock

Sale

Transaction value: $30,969
Shares: -14,036
Change %: -0.63%
Price: $2.21
Shares after: 2,230,052
Date: 25 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F3

ACRV holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 385,859
Date: 25 Aug 2026
Ownership: See Footnote
Footnotes: F4

ACRV holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 385,859
Date: 25 Aug 2026
Ownership: See Footnote
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Footnote F2

The price reported in Column 4 above reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $2.17 to $2.25, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4.

Footnote F3

These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.

Footnote F4

These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.